interventional cardiology equipment

Interventional Cardiology Equipment: Top Advancements of 2020

Interventional Cardiology Equipment: Top Advancements of 2020

interventional cardiology equipment

You might be surprised to discover that there is a direct connection between developments in interventional cardiology equipment and social trends together with population profiles. Perhaps you’ve noticed discussions on rising percentages of the elderly demographic, people living with higher levels of stress, and many living sedentary lifestyles with unhealthy dietary habits. These groups are at the highest risk of living with cardiovascular diseases and count for as much as one-third of the world’s population. In the wake of Covid-19 most surgical procedures have been tabooed. We’ve also seen an increase in concern over easily communicable diseases (including Covid-19, HIV, Hep B, C, etc.) during surgical procedures.

In this time, Interventional Cardiology Procedures has seen tremendous medical success. This segment – worth billions of dollars, is expected to register a CAGR of 6.8% – 9.5% by 2025. So, it’s a good idea for growing OEMs to keep an eye on the manufacturing advances of these devices as well.

 

Schedule a Consultation with a Quasar Expert

Three areas within Interventional Cardiology technology that have seen significant advancements are:

  • Drug-eluting stents: The stents coated with specific drugs are extremely useful when placed in peripheral or coronary arteries. The drug is slowly released to prevent the formation of scar tissue and clotting – post-treatment.
  • Vascular Closure Devices: These may be metallic clips, sutures, or patches made from various materials and used to seal the puncture sites after an angiogram or a catheterization procedure.
  • Coronary guidewires: These wires are used to navigate through blood vessels and deliver devices such as a balloon catheter to the narrowed arterial site.

 

Another promising innovation is the use of bio-absorbable (biodegradable) materials in the manufacture of stents. Using such devices improves patients’ overall health by minimizing the predisposition to late stent thrombosis.

How Innovations Impact the Development of Interventional Cardiology Equipment

Innovations don’t simply happen – as you’ll agree. Individual researchers and R&D firms use research in biomedical engineering, clinical and other sciences to improve device functionality and solve problems associated with devices used in interventional cardiology.

We’ve witnessed incremental improvements (innovations) over the past three decades. That’s why medical device manufacturers must monitor the pulse of the industry constantly to stay up to date with the latest improvements. Skip a recent update and you’re likely to be stuck with inventory that has little or no demand.

The evolution of stenting materials

Take the evolution of stenting materials: You’ll find that they started out as non-degradable stainless steel, introduced nitinol (Nickel-Titanium alloys) that confer self-expandable properties to stents (which is a rarity among stents) and then evolved into biodegradable Magnesium. Stents are now set to be made with Zinc – which is Bio-adaptive, smart, and Anti-bacterial.

It often takes veteran manufacturers who are specialized in the field of interventional cardiology equipment, to be able to smoothly navigate through this ever-evolving market.

Focus for the future

At the end of the day, the healthcare sector and patients are inclined to choose safe and non-invasive medical procedures that avert possibly life-threatening conditions such as heart attacks, clotting of blood, blocked arteries, and other medical conditions. Veteran manufacturers such as Quasar – who has over thirty years of medical device manufacturing under its belt are ready and able to partner with you to bring out the next big interventional cardiology device.

 

 

Contract manufacturer

Read More

China MAH Policy

China MAH Policy Changes and The massive Opportunity for Medical Device OEMs

The new MAH or Marketing Authorization Holder Policy has opened up a whole new level of opportunities for medical device companies. OEMs must capitalize on the major changes taking place in the Chinese market in allowing high-quality medical devices to be manufactured and marketed without as many restrictions as they experienced prior to the MAH Policy.

Read more...
crisis leadership

The Impact of Quasar’s Crisis Leadership Through Covid-19

As rumors of Covid-19 spread in January 2020, and fear gripped most of China, the management had to face facts and realize that a serious crisis was in the offing. Instead of being paralyzed by fear and uncertainty, Quasar’s leadership headed by Ayal Amitai, CEO, began looking ahead, considering courses of action to get the plant working again.

Read more...